AlphAIalphai — Financial news for AI agents
fool.comAUG 203 min read$OMER

Omeros (OMER) Q2 2026 Earnings Call Transcript

Omeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.

Original reporting
fool.com
Published Aug 20, 2026, 12:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:07 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Omeros (OMER) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$OMERBullishHigh
01

Why it matters

The earnings beat and debt reduction could trigger buying pressure, while regulatory setbacks may temper enthusiasm.

02

Market read

The earnings release provides fresh material for traders to assess OMER's valuation and potential price movement.

03

What to watch

Potential regulatory risk from EMA negative opinion on Yartemlia marketing authorization.

Relevance 8/10Novelty 8/10Timing: post-earnings release today

Background

Omeros Corporation reported its Q2 2026 earnings, highlighting rapid adoption of its Yartemlia therapy and significant balance sheet improvements.

Company-level read

Ticker impact

$OMERBullishHigh confidence
Context

Q2 2026 earnings call disclosed $32.2M gross sales for Yartemlia, $13.2M net income and a $30.5M convertible note repurchase.

Expected impact

Potential upside of 5-10% in the near term as investors digest the earnings beat and balance sheet improvement.

Evidence & confidence

Revenue surged 190% YoY, cash flow turned positive, and debt was cut by 43%, indicating operational momentum.

Market effects

Sector

Biotech sector may see renewed interest in complement-targeting therapies.

Regional

U.S. biotech investors likely to react positively.

Global

Limited to OMER and related biotech peers.

Counterpoint

What could challenge this read

Some investors may question sustainability of rapid sales growth and reliance on Medicare reimbursement.

Key entities

  • Company
    Omeros Corporation

    Biopharma developer of complement-targeting therapies.

  • Partner
    Novo Nordisk

    Collaboration partner providing payments for inventory transfer.

Read at source← All news

Related articles

AUG 14
$OMERMed

Omeros Corporation Q2 2026 Earnings Call Summary

Omeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.

yahoo.com5 min
AUG 13
$OMERHighAI 9/10

Why is Omeros stock surging today?

Omeros (OMER) shares rose about 17% in pre-open after the company reported Q2 2026 results. Adjusted EPS was $0.02 versus a consensus $0.25 loss, and revenue was $28.5M versus $12.67M expected. YARTEMLEA sales were $32.2M gross, and Omeros reported GAAP net income of $13.2M and first positive operating cash flow.

investing.com4 min
AUG 12
$OMERMed

OMEROS CORP (OMER): Results of Operations and Financial Condition

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Second Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 12, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second q

SEC EDGAR 8-K7 min
JUL 28
$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

rttnews.com6 min